Načítá se...

Native-like aggregates of Factor VIII (FVIII) are immunogenic von Willebrand Factor deficient and hemophilia A mice

The administration of recombinant Factor VIII (FVIII) is the first line therapy for Hemophilia A (HA), but 25–35% of patients develop an inhibitory antibody response. In general, the presence of aggregates contributes to unwanted immunogenic responses against therapeutic proteins. FVIII has been sho...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Pisal, Dipak S., Kosloski, Matthew P., Middaugh, C. Russell, Bankert, Richard B., Balu-Iyer, Sathy V.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3774159/
https://ncbi.nlm.nih.gov/pubmed/22388918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jps.23091
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!